Skip to main content

Advertisement

SpringerLink
Log in

Inhibition of acyl coenzyme a-cholesterol acyltransferase: A possible treatment of atherosclerosis?

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Our full understanding of atherosclerosis and our ability to prevent its sequellae are incomplete. As a result, further investigation of novel antiatherosclerotic mechanisms and agents continues. Acyl coenzyme A-cholesterol acyltransferase (ACAT) inhibition has been evaluated as a potential mechanism by which the current treatment arsenal may be expanded. ACAT is present in a variety of tissues and is responsible for catalyzing the conversion of free cholesterol to the more readily stored cholesteryl esters. Impressive lipid effects demonstrated in animals have not generally been demonstrated in human clinical trials. Partial ACAT inhibition with specific agents has resulted in lesion regression and decreased progression, whereas complete ACAT inhibition via genetic alterations has led to an exacerbation of cholesterol deposition in tissues in animal models. No ACAT inhibitor has yet been fully evaluated in human clinical trials for its impact on atherosclerotic disease progression. Several hurdles, such as sample size requirements needed to detect effect over background therapy and lack of sensitive surrogate efficacy markers, have served as a deterrent to the development of this class of investigational drug. However, with recent technologic advancements, more sensitive methods of measuring disease progression may be available. Human clinical trials are currently underway, with several agents reported in Phase II clinical trials. Within the next few years, results from these trials may determine whether or not ACAT inhibitors will be added to the list of treatment options for the prevention of atherosclerotic disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Suckling KE, Stange EF: Role of acyl-CoA-cholesterol acyl-transferase in celular cholesterol metabolism. J Lipid Res 1985, 26:647–671.

    PubMed  CAS  Google Scholar 

  2. Kinnumen PM, De Michele A, Lange LG: Chemical modification of acyl-CoA-cholesterol acyltransferase. Identification of acyl-CoA-cholesterol acyltransferase sub-types by differential diethyl pyrocarbonate sensitivity. Biochemistry 1988, 27:7344–7350.

    Article  Google Scholar 

  3. Krause BR, Anderson M, Bisgaier CL, et al.: In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res 1993, 4:279–294.

    Google Scholar 

  4. Heider JG, Pickens CE, Kelly LA: Role of acyl CoA: cholesterol acyltransferase in cholesterol absorption and its inhibition of 57–118 in the rabbit. J Lipid Res 1983, 24:1127–1277.

    PubMed  CAS  Google Scholar 

  5. Vahouny GV, Fawal I, Treadwell CR: Factors facilitating cholesterol absorption from the intestine via lymphatic pathways. Am J Physiol 1957, 188:742–746.

    Google Scholar 

  6. Helgerud P, Saarem K, Norum KR: J Lipid Res 1981, 22:271–277.

    PubMed  CAS  Google Scholar 

  7. Bennett CS, Tercyak AM: Reduced cholesterol transmucosal transport in rats with inhibited mucosal acyl CoA:cholesterol acyltransferase and normal pancreatic function. J Lipid Res 1984, 25:148–159.

    Google Scholar 

  8. Largis EE, Wang CH, DeVries VG, Schaffer SA: CL277082, a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J Lipid Res 1989, 30:681–690.

    PubMed  CAS  Google Scholar 

  9. Salter AM, Ekins N, Al-Seeni M, et al.: Cholesterol esterification plays a major role in determining low-density-lipoprotein receptor activity in primary monolayer cultures of rat hepatocytes. Biochem J 1989, 263:255–260.

    PubMed  CAS  Google Scholar 

  10. Kruth HS, Comly ME, Butler JD, et al.: Type C Niemann-Pick disease: abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts. J Biol Chem 1986, 261:16769–16774.

    PubMed  CAS  Google Scholar 

  11. Liscum L, Ruggiero RM, Faust JR: The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts. J Cell Biol 1989, 108:1625–1636.

    Article  PubMed  CAS  Google Scholar 

  12. Cadigan KM, Spillane DM, Chang TY: Isolation and characterization of Chinese hamster ovary cell mutants defective in intracellular low density lipoprotein-cholesterol trafficking. J Cell Biol 1990, 110:295–308.

    Article  PubMed  CAS  Google Scholar 

  13. Chang TY, Doolittle GM: Acyl coenzyme A-cholesterol O-acyl-transferase. Enzymes 1983, 16:523–539.

    CAS  Google Scholar 

  14. Spady DK, Willard MN, Meidell RS: Role of acyl-coenzyme A: cholesterol acyltransferase-1 in the control of hepatic very low density lipoprotein secretion and low density lipoprotein receptor expression in the mouse and hamster. J Biol Chem 2000, 275:27005–27012.

    PubMed  CAS  Google Scholar 

  15. Khan B, Wilcox HG, Heimberg M: Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J 1989, 259:807–816.

    Google Scholar 

  16. Krause BR, Auerbach BJ: ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL. 11th International Symposium on Atherosclerosis. Paris, October 1997.

  17. Carr TP, Hamilton RL, Rudel LL: ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res 1995, 36:25–36.

    PubMed  CAS  Google Scholar 

  18. Cianflone KM, Yasruel Z, Rodriguez MA, et al.: Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to fatty acid challenge. J Lipid Res 1990, 31:2045–2055.

    PubMed  CAS  Google Scholar 

  19. Insull W, Koren M, Davignon J, et al.: Efficacy and short- term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001, 157:137–144.

    Article  PubMed  CAS  Google Scholar 

  20. Wilcox LJ, Barrett PH, Newton RS, et al.: ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol 1999, 19:939–949.

    PubMed  CAS  Google Scholar 

  21. Burnett JR, Wilcox LJ, Telford DE, et al.: Inhibiton of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 1999, 40:1317–1327.

    PubMed  CAS  Google Scholar 

  22. Huff MW, Telford DE, Barrett PH, et al.: Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arteriosclerosis 1994, 14:1498–1508.

    CAS  Google Scholar 

  23. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983, 52:223–261.

    Article  PubMed  CAS  Google Scholar 

  24. Libby P, Geng YJ, Aikawa M, et al.: Macrophages and atherosclerosis plaque stability Curr Opin Lipidol 1996, 7:330–335.

    Article  PubMed  CAS  Google Scholar 

  25. Brecher PI, Chobanian AV: Cholesteryl ester synthesis in normal and atherosclerotic aortas of rabbit and rhesus monkeys. Circ Res 1974, 35:692–701.

    PubMed  CAS  Google Scholar 

  26. Azuma Y, Kawasaki T, Ikemoto K: Effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase inhibitor on cholesterol esterification and high-density lipoprotein-induced cholesterol efflux in macrophages. Jpn J Pharmacol 1999, 79:159–167.

    Article  PubMed  CAS  Google Scholar 

  27. Chang TY, Chang CC, Chang D: Acyl-cpoenzyme A: cholesterol acyltr4ansferase. Am Rev Biochem 1997, 66:613–638.

    Article  CAS  Google Scholar 

  28. Warner GJ, Stoudt G, Bamberger M, et al.: Cell toxicity induced by inhibition of acyl coenzyme A: cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem 1995, 270:5772–5778.

    Article  PubMed  CAS  Google Scholar 

  29. Kellner-Weibel G, Jerone WG, Small DM, et al.: Effects of intracellular free cholesterol accumulation on macrophage viability, a model for foam cell death. Arterioscler Thromb Vasc Biol 1998, 18:423–431.

    PubMed  CAS  Google Scholar 

  30. Rodriguez A, Bachorik PS, Wee SB: Novel effects of the acylcoenzyme A: cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1999, 19:2199–2206.

    PubMed  CAS  Google Scholar 

  31. Rodriguez A, Wee SK, Usher DC: The acyl-CoA: cholesterol acyltransferase inhibitor, avasimibe, effectively limits lipid storage in human macrophages. Circulation 1999, 100:613.

    Google Scholar 

  32. Dominick MA, McGuire EJ, Reindel JF, et al.: Subacute toxicity of a novel inhibitor of Acyl-CoA: cholesterol acyltransferase in beagle dogs. Fundamental Applied Toxicol 1993, 20:217–224.

    Article  CAS  Google Scholar 

  33. Aurecchia S, Orloff D, Sobel S: Regulatory concerns at various phases of drug development. Am J Cardiol 1998, 81:2F-4F.

    Article  PubMed  CAS  Google Scholar 

  34. Nicolosi RJ, Wilson TA, Krause BR: The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998, 137:77–85.

    Article  PubMed  CAS  Google Scholar 

  35. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al.: Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE 3-Leiden mice. Circulation 2001, 103:1778–1786.

    PubMed  CAS  Google Scholar 

  36. Bocan TM, Mueller SB, Brown EQ, et al.: HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis 1998, 139:21–30.

    Article  PubMed  CAS  Google Scholar 

  37. Matsuo M, Ito F, Konto A, et al.: Effect of FR 145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochimica et Biophysica Acta 1995, 1259:254–260.

    PubMed  Google Scholar 

  38. Asami Y, Yamagishi I, Akiyoshi K, et al.: Inhibitory effects of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters. Atherosclerosis 1999, 146:237–242.

    Article  PubMed  CAS  Google Scholar 

  39. Matsui Y, Horiuchi K, Yamamoto K, Kanai K: Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor in cholesterol-fed rats, hamsters, and rabbits. Jpn J Pharmacol 2001, 85:423.

    Article  PubMed  CAS  Google Scholar 

  40. Perrey S, Legendre C, Matsuura A, et al.: Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis 2001, 155:359–370.

    Article  PubMed  CAS  Google Scholar 

  41. Fazio S, Major AS, Swift LL, et al.: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001, 107:163–171.

    Article  PubMed  CAS  Google Scholar 

  42. Kusunoki J, Hansoty DK, Aragane K, et al.: Acyl-CoA: Cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001, 103:2604–2609.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pfizer Global Research, 2800 Plymouth Road, 48105, Ann Arbor, MI, USA

    Therese M. Heinonen DVM

Authors
  1. Therese M. Heinonen DVM
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heinonen, T.M. Inhibition of acyl coenzyme a-cholesterol acyltransferase: A possible treatment of atherosclerosis?. Curr Atheroscler Rep 4, 65–70 (2002). https://doi.org/10.1007/s11883-002-0064-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-002-0064-9

Keywords

Search

Navigation